The Generic Drug User Fee Act sets in motion the administrative steps needed to better fund the Agency's review of generic drug products. The goal is to bring this review time down to under a year.
The FDA Safety and Innovation Act (FDASIA) includes a provision that allows sponsors to request their drug be designated as a "Breakthrough Therapy". Sponsors can submit requests for Breakthrough Therapy designation.